Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Long-Term Deferred Tax (2016)

Historic Long-Term Deferred Tax for Eledon Pharmaceuticals (ELDN) over the last 4 years, with Q4 2016 value amounting to $65.6 million.

  • Eledon Pharmaceuticals' Long-Term Deferred Tax rose 2864.11% to $65.6 million in Q4 2016 from the same period last year, while for Dec 2016 it was $65.6 million, marking a year-over-year increase of 2864.11%. This contributed to the annual value of $65.6 million for FY2016, which is 2864.11% up from last year.
  • As of Q4 2016, Eledon Pharmaceuticals' Long-Term Deferred Tax stood at $65.6 million, which was up 2864.11% from $51.0 million recorded in Q4 2015.
  • Eledon Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $65.6 million during Q4 2016, with a 5-year trough of $24.4 million in Q4 2013.
  • Moreover, its 4-year median value for Long-Term Deferred Tax was $42.2 million (2014), whereas its average is $43.6 million.
  • In the last 5 years, Eledon Pharmaceuticals' Long-Term Deferred Tax soared by 5336.62% in 2015 and then soared by 2864.11% in 2016.
  • Over the past 4 years, Eledon Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $24.4 million in 2013, then surged by 36.35% to $33.3 million in 2014, then soared by 53.37% to $51.0 million in 2015, then increased by 28.64% to $65.6 million in 2016.
  • Its Long-Term Deferred Tax stands at $65.6 million for Q4 2016, versus $51.0 million for Q4 2015 and $33.3 million for Q4 2014.